Orphazyme plummets following receipt of complete response letter from FDA for arimoclomol Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- CAI International (CAI) up 46% after entering into an agreement to be acquired by Mitsubishi HC Capital in an all-cash transaction for $56.00 per share, which represents a total equity value of approximately $1.1B
- Geron (GERN) up 15% after announcing the publication of data from the IMbark Phase 2 clinical trial in the Journal of Clinical Oncology
- Cleveland BioLabs (CBLI) up 6% after announcing that its registration statement on Form S-4 filed in connection with its previously announced merger with Cytocom was declared effective by the SEC
UP AFTER EARNINGS -
- Smith & Wesson Brands (SWBI) up 5%
- Adobe (ADBE) up 2%
LOWER -
- Orphazyme (ORPH) down 52% after receiving a complete response letter from the FDA that said more data was needed following its review of the new drug application for arimoclomol
- Athira Pharma (ATHA) down 42% after the determination to place Leen Kawas, president and CEO of Athira, on temporary leave pending a review of actions stemming from doctoral research Kawas conducted while at Washington State University
- Capstone Green Energy (CGRN) down 25% after a 1.9M share spot secondary priced at $5.25
- Nouveau Monde (NMG) down 14% after a 7M share secondary priced at $7.50
Symbols:
CAI GERN CBLI SWBI ADBE ORPH ATHA CGRN NMG Keywords: Fly Intel, Wall Street, Top Stories, Stocks